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Aim: Familial hypercholesterolemia (FH) is caused by mutations of FH genes i.e. 
LDL-receptor (LDLR), PCSK9 and apolipoprotein B (ApoB) gene. We evaluated the 
usefulness of DNA analysis for the diagnosis of homozygous FH (homo-FH), and 
studied the frequency of FH in the Hokuriku district of Japan. 
Methods: Twenty-five homo-FH patients were recruited. LDLR mutations were 
identified using the Invader assay method. Mutations in PCSK9 were detected by 
PCR-SSCP followed by direct sequence analysis. 
Results: We confirmed 15 true homozygotes and 10 compound heterozygotes for LDLR 
mutations. Three types of double heterozygotes for LDLR and PCSK9 were found. No 
FH patients due to ApoB mutations were found. The incidences of homo-FH and 
hetero-FH in the Hokuriku district were 1/171,167 and 1/208, respectively. 
Conclusions: Our observations underlined the value of FH gene analysis in diagnosing 







   Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized 
by the triad of (1) hypercholesterolemia due to a high level of plasma low-density- 
lipoprotein (LDL), (2) tendon xanthomas and (3) premature coronary heart disease [1]. 
Patients with homozygous FH (homo-FH) have two mutant alleles of either of three 
FH-associated genes (FH genes), which are as follows: LDL-receptor (LDLR), 
proprotein convertase subtilisin/kexin type 9 (PCSK9) and apolipoprotein B (ApoB) 
gene [2]. Homo-FH patients are likely to be identified in early childhood because of the 
early appearance of xanthomatosis associated with an exceptionally high plasma 
cholesterol levels (exceeding 15.6 mmol/l), reflecting an extreme increase in LDL 
concentration. Use of the classical diagnosis of homo-FH and hetero-FH has led to an 
estimate of the prevalence of homo- and hetero-FH is 1 in 1,000,000 and 1 in 500 
persons, respectively throughout the world [1]. The clinical phenotype of FH is highly 
variable and depends on the FH genes mutations present. Patients with a mild 
phenotype of homozygous FH often show a heterozygous phenotype of FH. Our aims of 
the present study were two. First we evaluated the molecular genetic epidemiology of 
homo-FH and then studied the frequency of hetero- and homo-FH in the Hokuriku 
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district of Japan.  
 
2. Patients and methods 
 
2.1. Diagnostic criteria of FH [3][4] 
 
I. Hetero-FH 
a) Clinical diagnostic criteria are hypercholesterolemia with tendon 
xanthomas, or hypercholesterolemia in the first- or second-degree relative 
of FH patients. 
 b) Genetic diagnostic criteria are mutations of FH genes.  
II. Homo-FH 
a) Clinical diagnostic criteria are juvenile xanthomatosis with plasma cholesterol 
level about twice that of parents or other family members with hetero-FH 
b) Genetic diagnostic criteria are true homozygotes, compound heterozygotes 
and double heterozygotes for FH genes. 
 
2.2. Patients  
 
   Twenty-five clinically or genetically diagnosed homo-FH patients were selected for 
the study of genetic epidemiology of homo-FH and the calculation of the incidence of 
FH in the Hokuriku district. Written informed consent was obtained from each of the 
subjects prior to participation in the study.  
 
2.3. Laboratory measurements   
 
   Blood samples for assays were drawn after overnight fasting. Concentrations of 
plasma total cholesterol (TC), triglyceride (TG) and high-density-lipoprotein- 
cholesterol (HDL-C) were determined at accredited clinical laboratories using routine 
clinical methods. LDL-cholesterol (LDL-C) concentrations were calculated using the 
Friedewald equation [5].  
 
2.4. FH genes analysis   
 
   Detailed methods of FH genes analysis were described in our previous paper [6], 
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and are described in brief here. Genomic DNA was prepared from white blood cells 
using a Genomic DNA Purification Kit (Gentra Systems, Minneapolis, MN, USA). 
Primers covering all of the exons and exon–intron boundary sequence of LDLR and 
PCSK9 were designed using Primer3 online software (http://frodo.wi.mit.edu/). LDLR 
mutations were identified using the Invader assay method (Third Wave Technologies, 
Inc., Madison, WI, USA) for point mutations previously identified in Japan [7]. The 
multiplex ligation-dependent probe amplification (MLPA) method for large 
rearrangements was performed using a P062B LDLR MLPA kit (MRC Holland, 
Amsterdam, Netherlands) and DNA sequencing was performed using a BigDye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) for 
the other mutations. ApoB mutations were screened by the methods reported in our 
previous paper [8]. Mutations in PCSK9 were detected by polymerase chain reaction 
(PCR) single-strand conformational polymorphism (SSCP) followed by direct sequence 
analysis.  
 
2.5. Statistical analysis 
 
   Plasma lipid concentrations were compared among FH groups using Student’s t-test. 
All data in the text are expressed as mean ± SD. JMP 5.1.2 software (SAS Institute, 





3.1. Genotypic analyses of homo-FH patients 
 
   A DNA study of FH gene mutations was performed in all 25 clinically and 
genetically diagnosed homo-FH patients. Thirteen LDL-R mutants were found in these 
homo-FH patients, and one PCSK9 mutant (PCSK9 E32K) was found in five patients 
(Table 1). True homo-FH was confirmed in 15 patients (Table 1, Fig. 1), and six true 
homozygotes (13 patients) were for LDLR mutations, and one (2 patients) was true 
homozgyote for PCSK9 E32K. Four true homozygotes of Ex2-3del in three families and 
three homozygotes of D280Y in one family were born to consanguineous marriage. The 
geographical distributions of these homo-FH patients are shown in Fig. 1. Nine types of 
compound LDLR mutations were found in 10 homo-FH patients. Three types of LDLR 
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and PCSK9 double heterozygotes were found. No case of FH patients due to ApoB 
mutation was found. No consanguineous marriage was found in these compound or 
double heterozygote families (Table 1, Fig. 1). 
   Thirteen cases diagnosed by DNA analysis showed less than 14.3 mmol/L of TC. 
Mean (±SD) TC levels (15.7±4.0 mmol/L) in homo-FH patients confirmed by DNA 
analysis were significantly lower than those (18.5±4.1 mmol/L) diagnosed by clinical 
criteria (p < 0.0442) [9]. Two patients who were true homozygotes due to a mutation in 
the PCSK9 gene were newly found among our homozygotes. PCSK9 E32K produced 
relatively mild homo-FH phenotypes. The mean (±SD) plasma cholesterol level in 
homozygotes for LDLR gene mutations (15.7±3.8 mmol/L) was significantly higher 
than that (11.3±3.2 mmol/L) in true homozygotes or double heterozygotes for PCSK9 
mutations (p < 0.0276).  
   The outcomes of the patients are shown in Table 1. Seven patients died of cardiac 
death and one (M.K.) died of leukemia. Seventeen patients are alive, and 6 patients have 
been treated with LDL-apheresis, and 11 patients with medications (Table 1). 
 
3.2. Frequency of FH calculated using the Hardy-Weinberg equilibrium 
 
   Among 11 true homo-FH families consanguineous marriage was detected in four. In 
the remaining seven families, there were no consanguineous marriages. In nine families 
of compound heterozygotes no consanguineous marriage was found (Table 1, Fig. 1). 
The Hardy-Weinberg equilibrium was used to calculate the frequency of hetero-FH. The 
frequencies of homo-FH, hetero-FH and unaffected persons are p2, 2pq and q2, 
respectively (where p + q = 1) and the general population in the Hokuriku district was 
3,081,000. If the 7 patients from consanguineous marriage were ignored, p2 could be 
18/3,081,000 = 1/171,167 and then p = 1/414. As q = 1 – p = 413/414, the frequency of 
the hetero-FH (2pq) is 2 × 1/414 ×413/414 = 1/208. Therefore, frequencies of the 




   It has been thought that homo-FH is easily diagnosed. However, it is sometimes 
difficult to differentiate severely affected heterozygotes from mild-type homozygotes 
without DNA analysis of FH genes. Recently, analysis of FH gene mutations has made 
it possible to identify presymptomatic homo-FH phenotype. DNA analysis of 
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FH-associated genes shows true homozygote of identical heterozygous mutant, 
compound heterozygote of different heterozygous mutant of the same gene, and double 
heterozygote of different FH gene mutations. True homozygotes often came from a 
consanguineous marriage, whereas compound or double heterozygotes almost never did 
so. True homozygotes and compound heterozygotes for PCSK9 E32K show mild 
phenotypic homo-FH, compared with LDLR mutant homo-FH patients [6]. Currently, 
the diagnosis of FH involves clinical assessment and biochemical tests (lipid profile), 
but DNA-based testing will play a greater role in the identification and management of 
FH [10].  
  The prevalence of hetero-FH among the general population has been estimated to be 
at least, 1 in 500 among Caucasians, ranging from 1 in 200 to 1 in 1000 [11, 12]. In 
1978, we summarized 51 homozygous patients with FH in Japan, and estimated the 
frequency of homo-FH in Japan as 1 in 1.45 millions, and that of hetero-FH as 1 in 500 
[9]. However, the low incidence of FH in most countries is due to the low frequency of 
homo-FH diagnosed by classical diagnostic criteria based on physical signs, laboratory 
findings and data from the parents. In the present study genetic diagnosis detected 
unexpectedly mild phenotypic cases of homo-FH, and several new cases of homo-FH 
were discovered. As FH is an autosomal dominant genetic disease, the frequency of 
hetero-FH has been calculated by the incidence of homo-FH in the district using the 
Hardy-Weinberg equilibrium. Here we found an extraordinarily high incidence of FH in 
this district of Japan.  
  A remarkably high prevalence of FH has been reported in several areas of the world, 
owing to founder effects. In Lebanon, the estimated prevalence of homozygotes and 
heterozygotes is 1 in 10,000 and 1 in 171, respectively [13]. In the Hokuriku district of 
Japan, the most frequent mutation in hetero-FH was the K790X LDLR mutation, with a 
frequency of 31.7% [7]. However, this mutant was less frequent in the Osaka district 
(5.4%) in Japan. No historical immigration records have been maintained in this district, 
and thus the K790X mutant of LDLR should not be classified as a founder gene in 
Japan, but only as a historically old mutant that prevailed locally and widely over a long 
period of time. High frequency of FH gene mutations might have produced true 
homozygotes without consanguineous marriage. 
  These observations underline the value of gene analysis in diagnosing hetero- and 
homo-FH patients and the extraordinarily high frequency of FH in this district of Japan. 
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Fig.1. Geographical location of 25 homo-FH patients with FH gene mutations in the 
Hokuriku district of Japan 
 
Table 1       
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